A Clinical Study of Otitis Externa with Bacterial Isolation, Antimicrobial Susceptibility and Therapeutic Management in 44 Dogs

dc.contributor.authorSelvakumar, S.
dc.contributor.authorAli, M.G. Mohamed
dc.contributor.authorPothiappan, P.
dc.contributor.authorTANUVAS
dc.date.accessioned2016-06-01T11:28:16Z
dc.date.available2016-06-01T11:28:16Z
dc.date.issued2015-07
dc.description.abstractThe study included 44 dogs with clinical signs specific for otitis externa. The microbiological tests showed that 35 isolates with typical characteristic of genus S. aureus (79%). No isolate from 4 samples and isolate of gram negative bacteria and yeast from 5 dogs were eliminated from this study. The most active antimicrobial agents against Staphylococci isolated from otitis externa of dogs were Cephalexin and Penicillin. The organism is much resistant to Azithromycin (7.78%), Ciprofloxacin (55.56%), Gatifloxacin (44.44%) and Piperacillin (55.56%). Based on antimicrobial susceptibility, all the animals were treated with Tab. Cephalexin 25 mg/kg b.w.t. BID orally, Tab. Prednislone 1 mg/kg b.wt. orally for seven days and Otic drops twice daily for 7 days. After a week, all the animals showed marked clinical improvement in the form of reducing signs of erytherna, swelling, otohhroea, pain and itch.en_US
dc.identifier.urihttp://krishikosh.egranth.ac.in/handle/1/66523
dc.language.isoenen_US
dc.publisherINTAS Poliveten_US
dc.subjectAntimicrobialen_US
dc.subjectDogen_US
dc.subjectManagementen_US
dc.subjectOtitis externaen_US
dc.titleA Clinical Study of Otitis Externa with Bacterial Isolation, Antimicrobial Susceptibility and Therapeutic Management in 44 Dogsen_US
dc.title.alternativeIntas Polivet (2015) Vol.16 (II): 332-333en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
POLIVET_TANUVAS_V16_I2_Pg332-333.pdf
Size:
1.7 MB
Format:
Adobe Portable Document Format
Description:
Article
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.28 KB
Format:
Item-specific license agreed upon to submission
Description: